Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Tarsus Pharmaceuticals Inc(TARS)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TARS
11/12/2026: TARS (4-star) is currently NOT-A-BUY. Pass it for now.
Tarsus Pharmaceuticals is a commercial-stage biotechnology company focused on treating ophthalmic conditions, highlighted by its lead FDA-approved drug, XDEMVY, for Demodex blepharitis. The company's main strength lies in its first-mover advantage and the successful commercialization of a product addressing a high-unmet need. Its primary investment story centers on the continued market adoption of XDEMVY and potential label expansion. Investors must weigh these growth opportunities against risks, including single-product reliance, competitive pressure, and the need to scale commercial operations profitability. Tarsus may best suit growth-oriented investors, and stakeholders should monitor quarterly sales data and regulatory progress for pipeline assets.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an early commercial growth phase with significant potential for market expansion. |
| Momentum investor | Strong fit while signal remains positive | Market adoption of XDEMVY provides potential for positive price momentum if uptake targets are met. |
| Value investor | Weak fit | The company is not currently profitable and trades based on future growth expectations rather than current earnings. |
| Dividend investor | Weak fit | The company does not pay a dividend and is focused on reinvesting capital. |
| Low-risk investor | Weak fit | Biotech stocks in the commercial ramp-up phase are subject to high volatility and operational risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech commercialization often leads to significant stock price swings based on sales data. |
| Valuation risk | Medium / high | The stock price is driven by long-term growth expectations rather than current earnings. |
| Competition risk (Ophthalmic) | Medium | Major players could introduce competing therapies or increase focus on the same patient segments. |
| Business quality | Medium | The company is in the early stages of establishing its long-term commercial track record. |
| Dividend income | Low / none | No capital is returned to shareholders through dividends. |
| Execution risk | Medium / high | Success depends on effectively scaling sales and gaining market acceptance for a new drug class. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.78B USD | Price to earnings Ratio - | 1Y Target Price 103.44 |
Price to earnings Ratio - | 1Y Target Price 103.44 | ||
Volume (30-day avg) 975.7K shares | Beta 0.33 | 52 Weeks Range 53.89 - 91.53 | Updated Date 11/12/2026 |
52 Weeks Range 53.89 - 91.53 | Updated Date 11/12/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.86 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 135.71% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/12/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Ophthalmic Pharmaceuticals | Revenue from sales of XDEMVY and future potential therapies for eye diseases. | The company makes money by selling a specialized eye medication that treats a specific condition. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 61.35 | Enterprise Value 3.40B | Price to Sales(TTM) 5.55 |
Enterprise Value 3.40B | Price to Sales(TTM) 5.55 | ||
Enterprise Value to Revenue 4.99 | Enterprise Value to EBITDA -3.23 | Shares Outstanding 49.31M | Shares Floating 38.15M |
Shares Outstanding 49.31M | Shares Floating 38.15M | ||
Percent Insiders 2.69 | Percent Institutions 104.47 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.